TriSalus Life Sciences (TLSI) Competitors $3.80 +0.15 (+4.22%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI vs. AXGN, EMBC, CBLL, ZIMV, KIDS, BVS, SMLR, SI, AVNS, and DCTHShould you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include AxoGen (AXGN), Embecta (EMBC), CeriBell (CBLL), ZimVie (ZIMV), OrthoPediatrics (KIDS), Bioventus (BVS), Semler Scientific (SMLR), Shoulder Innovations (SI), Avanos Medical (AVNS), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry. TriSalus Life Sciences vs. Its Competitors AxoGen Embecta CeriBell ZimVie OrthoPediatrics Bioventus Semler Scientific Shoulder Innovations Avanos Medical Delcath Systems TriSalus Life Sciences (NASDAQ:TLSI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Does the media prefer TLSI or AXGN? In the previous week, AxoGen had 9 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 15 mentions for AxoGen and 6 mentions for TriSalus Life Sciences. AxoGen's average media sentiment score of 0.76 beat TriSalus Life Sciences' score of 0.03 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TLSI or AXGN? TriSalus Life Sciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. Do analysts rate TLSI or AXGN? TriSalus Life Sciences currently has a consensus price target of $10.75, suggesting a potential upside of 182.60%. AxoGen has a consensus price target of $26.00, suggesting a potential upside of 77.51%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe TriSalus Life Sciences is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25AxoGen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, TLSI or AXGN? AxoGen has higher revenue and earnings than TriSalus Life Sciences. AxoGen is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTriSalus Life Sciences$29.43M4.89-$30.05M-$1.12-3.40AxoGen$203.27M3.32-$9.96M-$0.10-146.47 Is TLSI or AXGN more profitable? AxoGen has a net margin of -2.29% compared to TriSalus Life Sciences' net margin of -84.67%. TriSalus Life Sciences' return on equity of 0.00% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences-84.67% N/A -111.63% AxoGen -2.29%-4.43%-2.34% Do insiders & institutionals hold more shares of TLSI or AXGN? 2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by insiders. Comparatively, 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAxoGen beats TriSalus Life Sciences on 9 of the 17 factors compared between the two stocks. Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSI vs. The Competition Export to ExcelMetricTriSalus Life SciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.94M$10.62B$5.62B$9.81BDividend YieldN/A2.00%4.64%4.14%P/E Ratio-3.4020.4130.1125.72Price / Sales4.8924.90463.22174.39Price / CashN/A23.7337.7258.50Price / Book-4.583.098.456.06Net Income-$30.05M$211.77M$3.26B$265.11M7 Day Performance-3.70%8.57%3.34%2.65%1 Month Performance-22.21%9.68%5.72%3.71%1 Year Performance-32.79%-6.97%42.58%26.59% TriSalus Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSITriSalus Life Sciences3.0145 of 5 stars$3.80+4.2%$10.75+182.6%-37.5%$143.94M$29.43M-3.40106News CoverageEarnings ReportGap UpHigh Trading VolumeAXGNAxoGen2.5304 of 5 stars$13.49+7.5%$24.50+81.7%+30.3%$615.47M$187.34M-90.09450News CoverageGap UpHigh Trading VolumeEMBCEmbecta4.754 of 5 stars$9.68-1.1%$19.00+96.3%-9.7%$566.02M$1.08B10.762,100Earnings ReportDividend AnnouncementCBLLCeriBell2.4414 of 5 stars$14.98-1.7%$32.14+114.6%N/A$541.38M$65.44M0.00N/AZIMVZimVie0.9651 of 5 stars$18.79+0.1%$17.75-5.5%+7.7%$530.02M$449.75M-26.851,770Positive NewsKIDSOrthoPediatrics3.9571 of 5 stars$20.31-1.1%$35.83+76.5%-23.9%$492.36M$204.73M-11.58200BVSBioventus2.9602 of 5 stars$5.86-7.4%$13.75+134.8%-3.3%$480.95M$567.70M-9.601,200News CoverageAnalyst RevisionSMLRSemler Scientific3.1515 of 5 stars$34.55-2.3%$82.00+137.4%+25.6%$476.61M$56.29M-13.24120SIShoulder InnovationsN/A$14.15-0.8%N/AN/A$447.98M$34.57M-0.4761Positive NewsAVNSAvanos Medical1.6369 of 5 stars$9.52-15.4%N/A-51.7%$437.57M$687.80M-1.132,227DCTHDelcath Systems2.8295 of 5 stars$10.50-6.9%$24.00+128.7%+45.6%$367.28M$37.21M-21.0960News CoverageEarnings ReportAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies AxoGen Competitors Embecta Competitors CeriBell Competitors ZimVie Competitors OrthoPediatrics Competitors Bioventus Competitors Semler Scientific Competitors Shoulder Innovations Competitors Avanos Medical Competitors Delcath Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSI) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access